Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers. Issue 3 (9th May 2022)

• Record Type: Journal Article
• Authors: Vourvahis, Manoli; Byon, Wonkyung; Chang, Cheng; Le, Vu; Diehl, Annette; Graham, Daniela; Tripathy, Sakambari; Raha, Nancy; Luo, Lina; Mathialagan, Sumathy; Dowty, Martin; Rodrigues, A. David; Malhotra, Bimal
• Is Part Of: Clinical pharmacology & therapeutics. Volume 112:Issue 3(2022)
• Page Start: 665
• Page End: 675
• Publication Date: 2022-05-09
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2594
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor currently approved in the United Kingdom for the treatment of moderate‐to‐severe atopic dermatitis (AD). As patients with AD may use medications to manage comorbidities, abrocitinib could be used concomitantly with hepatic and/or renal transporter substrates. Therefore, we assessed the potential effect of abrocitinib on probe drugs and endogenous biomarker substrates for the drug transporters of interest. In vitro studies indicated that, among the transporters tested, abrocitinib has the potential to inhibit the activities of P‐glycoprotein (P‐gp), breast cancer resistance protein (BCRP), organic anion transporter 3 (OAT3), organic cation transporter 1 (OCT1), and multidrug and toxin extrusion protein 1 and 2K (MATE1/2K). Therefore, subsequent phase I, two‐way crossover, open‐label studies in healthy participants were performed to assess the impact of abrocitinib on the pharmacokinetics of the transporter probe substrates dabigatran etexilate (P‐gp), rosuvastatin (BCRP and OAT3), and metformin (OCT2 and MATE1/2K), as well as endogenous biomarkers for MATE1/2K (N 1 ‐methylnicotinamide (NMN)) and OCT1 (isobutyryl‐L ‐carnitine (IBC)). Co‐administration with abrocitinib was shown to increase the plasma exposure of dabigatran by ~ 50%. In comparison, the plasma exposure and renal clearance of rosuvastatin and metformin were not altered with abrocitinib co‐administration. Similarly, abrocitinib did not affect the exposure of NMN or IBC. An increase in dabigatran exposure suggests that abrocitinib inhibits P‐gp activity. By contrast, a lack of impact on plasma exposure and/or renal clearance of rosuvastatin, metformin, NMN, or IBC suggests that BCRP, OAT3, OCT1, and MATE1/2K activity are unaffected by abrocitinib.